10-Q: Avadel Soars on Alkermes Acquisition, Strong LUMRYZ Growth

Avadel Pharmaceuticals reports significant revenue growth and profitability, driven by LUMRYZ sales, and announces its acquisition by Alkermes plc for $18.50 cash plus a $1.50 CVR per share.

Summary

• Avadel Pharmaceuticals plc will be acquired by Alkermes plc for $18.50 in cash and a non-transferable contingent value right (CVR) of $1.50 per share, contingent on specified milestones, with the transaction expected to close in Q1 2026.
• Net product revenue for the three months ended September 30, 2025, increased by 54.9% to $77.467 million, and for the nine months, it rose by 66.9% to $198.107 million, primarily due to increased LUMRYZ patient uptake.
• The company achieved operating income of $1.937 million for the three months and $7.820 million for the nine months ended September 30, 2025, a significant turnaround from losses in the prior year periods.
• Net income for the three months was $20,000 and for the nine months was $4.765 million, compared to net losses of $2.625 million and $43.789 million, respectively, in the prior year.
• Avadel CNS Pharmaceuticals LLC settled multiple lawsuits with Jazz Pharmaceuticals, Inc. on October 21, 2025, resulting in a $90 million payment from Jazz to Avadel and a waiver of past royalties on LUMRYZ sales through September 30, 2025.
• Under the settlement, Avadel will pay Jazz future royalties on LUMRYZ sales: 3.85% for narcolepsy indications and 10% for non-narcolepsy indications (effective March 1, 2028, with a conditional 80% rate for Q1 2028).
• Avadel entered an exclusive global license agreement with XWPharma Ltd. on August 30, 2025, for valiloxybate, involving an upfront payment of $20 million ($15 million already paid, $5 million due in Q4 2025) and potential future milestone payments.
• Research and development expenses significantly increased by 610.2% to $27.010 million for the three months and 226.1% to $35.619 million for the nine months, largely due to the XWPharma upfront license fees and costs for the REVITALYZ trial.
• Cash, cash equivalents, and marketable securities increased by $17.8 million to $91.577 million at September 30, 2025, from $73.777 million at December 31, 2024.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook, primarily driven by the announced acquisition by Alkermes at a significant premium, strong commercial performance of LUMRYZ with substantial revenue growth and a return to profitability, and the favorable settlement of major litigation with Jazz Pharmaceuticals. These factors collectively reduce uncertainty and provide a clear, attractive value proposition for shareholders.

Positives

• Net product revenue for LUMRYZ increased by 54.9% to $77.467 million for the three months and 66.9% to $198.107 million for the nine months ended September 30, 2025, demonstrating strong commercialization success.
• The company achieved operating income of $1.937 million and net income of $20,000 for the three months ended September 30, 2025, a significant improvement from losses in the prior year.
• For the nine months ended September 30, 2025, Avadel reported operating income of $7.820 million and net income of $4.765 million, reversing substantial losses from the previous year.
• The settlement with Jazz Pharmaceuticals resulted in a $90 million payment to Avadel and a waiver of all past royalties and damages on LUMRYZ sales through September 30, 2025, significantly improving financial position and removing litigation uncertainty.
• The reversal of approximately $9.5 million in estimated royalties due to the Jazz settlement positively impacted the cost of products sold and gross profit.
• Patient uptake for LUMRYZ continues to increase, with approximately 3,400 patients on LUMRYZ as of September 30, 2025, up from 2,300 patients in the prior year.
• LUMRYZ was granted Orphan Drug Designation (ODD) from the FDA for the treatment of Idiopathic Hypersomnia (IH) on June 5, 2025, and a pivotal trial (REVITALYZ) is underway, expanding potential market opportunities.
• The acquisition by Alkermes plc at $18.50 cash plus a $1.50 CVR per share provides a clear and attractive valuation for shareholders.

Negatives

• Research and development expenses increased substantially by 610.2% for the three months and 226.1% for the nine months ended September 30, 2025, primarily due to the $20 million upfront license fees for valiloxybate and costs associated with the REVITALYZ trial.
• Selling, general and administrative expenses increased by 30.3% for the three months and 7.6% for the nine months ended September 30, 2025, driven by higher employee-related costs and commercialization efforts for LUMRYZ.
• Investment and other income, net, decreased by 71.3% for the nine months ended September 30, 2025, primarily due to lower interest income and higher foreign exchange losses.
• The royalty financing obligation carries a high effective interest rate, estimated at 25.2% as of September 30, 2025.

Risks

• Failure to complete, or delays in completing, the pending transaction with Alkermes could materially and adversely affect results of operations and share price, including potential adverse effects on business relationships and significant transaction costs.
• The Transaction Agreement limits Avadel's ability to pursue alternative transactions and conduct business outside the ordinary course without Alkermes' consent, potentially deterring other acquirers.
• Competition in the pharmaceutical industry is intense, with LUMRYZ facing competition from generic twice-nightly sodium oxybate formulations (e.g., Hikma, Amneal) and potential future products like orexin 2 receptor agonists.
• Third parties may claim that Avadel's products infringe their intellectual property rights, leading to significant costs, delays in market entry, or preclusion from commercialization.
• Significant political, trade, and regulatory developments, including tariffs and changes in U.S. federal policy, could have a material adverse effect on financial condition or results of operations.
• Irish law differs from U.S. law, potentially affording less protection to shareholders and subjecting takeover offers to Irish Takeover Rules, which may restrict the board's actions.
• Changes in tax law, such as the One Big Beautiful Bill Act or global minimum taxation initiatives (Pillar Two Model Rules), could adversely affect business and financial condition.
• The company's reliance on a single commercial product, LUMRYZ, makes it vulnerable to market acceptance, competition, and regulatory changes for that product.

Future Outlook

The company expects the acquisition by Alkermes plc to close in the first quarter of 2026. It anticipates completing enrollment for the pivotal REVITALYZ trial of LUMRYZ in Idiopathic Hypersomnia (IH) by the end of 2025, with data reporting and a supplemental New Drug Application submission expected in 2026. The company believes its existing cash, cash equivalents, marketable securities, and anticipated sales of LUMRYZ will provide sufficient capital for the next twelve months, assuming the Alkermes transaction is not consummated.

Management Comments

• Management attributes the increase in net product revenue to the early phases of LUMRYZ launch in the prior period and continued patient uptake throughout the launch.
• Management notes that the decrease in cost of products sold for the three and nine months ended September 30, 2025, was due to the reversal of approximately $9.5 million of estimated royalties following the Jazz settlement, offset by higher LUMRYZ sales.
• Management highlights that the increase in R&D expenses was primarily driven by the upfront license fees to XWPharma and development costs for the valiloxybate drug candidate, as well as clinical work for the REVITALYZ trial.
• Management states that the increase in SG&A expenses was due to LUMRYZ commercial costs, including higher employee-related costs, patient and market access, selling and marketing, medical education, and business development, partially offset by decreased legal costs.

Industry Context

Avadel operates in the highly competitive biopharmaceutical industry, specifically targeting sleep disorders. The success of LUMRYZ, an extended-release sodium oxybate, positions it against existing treatments like Jazz Pharmaceuticals' Xyrem and its authorized generics (Hikma, Amneal). The ongoing development of valiloxybate and the REVITALYZ trial for Idiopathic Hypersomnia indicate a strategy to expand its product portfolio and address broader sleep disorder markets. The industry faces challenges from healthcare reform, pricing pressures, and the increasing role of generics. The acquisition by Alkermes reflects ongoing consolidation and strategic positioning within the pharmaceutical sector, where larger players seek to integrate promising assets and pipelines.

Comparison to Industry Standards

• LUMRYZ's once-nightly dosing regimen is considered a major contribution to patient care over currently marketed, twice-nightly oxybate treatments, such as Jazz Pharmaceuticals' Xyrem, which requires nocturnal arousal for a second dose.
• The market for narcolepsy treatments is competitive, with generic versions of Jazz's Xyrem (e.g., from Hikma Pharmaceuticals plc and Amneal Pharmaceuticals, Inc.) already launched or approved, indicating a need for differentiated products like LUMRYZ.
• The development of orexin 2 receptor agonists by other companies represents a future competitive landscape for narcolepsy and other sleep disorders, potentially impacting LUMRYZ's long-term market share.
• Avadel's strategy to expand LUMRYZ into Idiopathic Hypersomnia (IH) with Orphan Drug Designation positions it to address an unmet medical need, similar to how other companies target rare diseases for market exclusivity and premium pricing.

Legal Proceedings

• Multiple lawsuits between Avadel CNS Pharmaceuticals LLC and Jazz Pharmaceuticals, Inc. (First, Second, Third, Fourth Jazz Complaints, and Avadel's First, Second, Third, Fourth, Fifth Complaints) were settled on October 21, 2025.
• The settlement included a $90 million payment from Jazz to Avadel, a waiver of Jazz's right to receive royalties/damages on LUMRYZ sales through September 30, 2025, and mutual dismissals with prejudice on October 27, 2025.
• Avadel will pay Jazz future royalties on LUMRYZ sales: 3.85% for narcolepsy and 10% for non-narcolepsy indications (with specific terms for Q1 2028).
• Jazz granted Avadel a non-exclusive, perpetual, irrevocable, royalty-bearing license under Jazz Licensed Patents for Avadel Licensed Products.
• Avadel granted Jazz a non-exclusive, perpetual, irrevocable, royalty-free covenant not to sue under Avadel Licensed Patents for Jazz Licensed Products.
• Jazz's Administrative Procedure Act Complaint against the FDA regarding LUMRYZ approval was affirmed in favor of FDA and Avadel by the D.C. Court of Appeals on June 27, 2025, upholding LUMRYZ's approval.

Related Party Transactions

• The royalty financing obligation with RTW Investments, L.P. for up to $75 million, with an effective interest rate estimated at 25.2% as of September 30, 2025. RTW exercised its put option contingent on the Alkermes transaction closing.

Stakeholder Impact

• Shareholders: Will receive $18.50 in cash and a CVR of $1.50 per share upon the closing of the Alkermes acquisition, representing a significant return. However, failure to close could lead to share price decline.
• Employees: May experience uncertainty regarding roles and retention during the pendency of the Alkermes acquisition.
• Customers (patients): Continued access to LUMRYZ for narcolepsy and potential future access for Idiopathic Hypersomnia, with the benefit of a once-nightly dosing regimen.
• Suppliers and Business Partners: Relationships may be affected by uncertainties surrounding the Alkermes acquisition and potential changes in business operations post-acquisition.
• Creditors (RTW Investments): The royalty financing obligation is subject to a put option exercised by RTW, contingent on the Alkermes acquisition closing, ensuring their investment is addressed.

Next Steps

• Alkermes acquisition expected to close in the first quarter of 2026, subject to shareholder approval, Irish High Court sanction, and U.S. antitrust clearances.
• Complete enrollment for the pivotal REVITALYZ trial of LUMRYZ in Idiopathic Hypersomnia (IH) by the end of 2025.
• Report data from the REVITALYZ trial and submit a supplemental New Drug Application (sNDA) for LUMRYZ in IH in 2026.
• Pay the remaining $5 million upfront payment to XWPharma Ltd. in the fourth quarter of 2025 for the valiloxybate license.

Key Dates

Recommendation

The announced acquisition by Alkermes plc at $18.50 cash plus a $1.50 CVR per share provides a clear valuation for Avadel's stock. Given the pending nature of the transaction and the stock likely trading close to the offer price, the upside for new investors is limited to the CVR's potential value. For existing shareholders, holding until the acquisition closes is the most logical strategy to realize the full value of the offer. The strong financial performance and litigation settlement are positive, but the acquisition caps the immediate share price potential.

Keywords

Avadel Pharmaceuticals, Alkermes Acquisition, LUMRYZ, Narcolepsy Treatment, Idiopathic Hypersomnia, XWPharma, Valiloxybate, Biopharmaceutical, SEC Filing, Q3 2025 Earnings, Jazz Pharmaceuticals Settlement, Orphan Drug Designation